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ORIGINAL ARTICLE
Performance, treatment pathways, and effects of
alternative policy options for screening for developmental
dysplasia of the hip in the United Kingdom
C Dezateux, J Brown, R Arthur, J Karnon, A Parnaby
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Arch Dis Child 2003;88:753–759
Aims: To compare, using a decision model, performance, treatment pathways and effects of different
newborn screening strategies for developmental hip dysplasia with no screening.
Methods: Detection rate, radiological absence of subluxation at skeletal maturity and avascular necro-
sis of the femoral head, as favourable and unfavourable treatment outcomes respectively, were com-
pared for the following strategies: clinical screening alone using the Ortolani and Barlow tests; the
addition of static and dynamic ultrasound examination of the hips of all infants (universal ultrasound)
or restricted to infants with defined risk factors (selective ultrasound); “no screening” (that is, clinical
diagnosis only).
Results: Universal or selective ultrasound detects more more affected children (76% and 60% respec-
tively) than clinical screening alone (35%), results in a higher proportion of affected children with
favourable treatment outcomes (92% and 88% respectively) than clinical screening alone (78%) or no
screening (75%), and the highest proportion of these achieved without recourse to surgery (64% and
79% respectively) compared with clinical screening alone (18%). However, ultrasound based
strategies are also associated with the highest number of unfavourable treatment outcomes arising in
unaffected children treated following a false positive screening result. The detection rate of clinical
screening alone becomes similar to that reported for universal ultrasound when based on studies using
experienced examiners (80%) rather than junior medical staff (35%).
Conclusion: From the largely observational data available, ultrasound based screening strategies
appear to be most sensitive and effective but are associated with the greatest risk of potential adverse
iatrogenic effects arising in unaffected children.
In 1966 a national screening programme was introduced inthe United Kingdom to identify newborn infants who areconsidered to be at increased risk of subsequent develop-
mental hip dysplasia (DDH; formerly referred to as congenital
dislocation of the hip).1 Under this programme, all infants are
examined using the Ortolani and Barlow tests to identify hip
dislocation or instability respectively. Those in whom these
signs persist are treated with abduction splinting to reduce
and stabilise the hip and prevent established or partial dislo-
cation (subluxation). This policy was last reviewed in 1986,
when the recommendation to perform a clinical screening
examination of the hips on all newborn and very young
infants was reinforced.2 The policy is currently under further
review by the National Screening Committee’s Child Health
Group.
The goal of this screening programme is to achieve normal
hip function and development by skeletal maturity in those
children who would otherwise have presented clinically with
DDH, while a subsidiary goal is to achieve this outcome with-
out recourse to surgery. At its inception, the rationale for the
screening programme was based on the then generally
accepted premise that DDH first diagnosed clinically after
walking age is likely to require complex surgical treatment
and to have a less successful outcome than if diagnosed
earlier. However, as the outcome of clinical screening has never
been compared to that of clinical diagnosis in a randomised
trial, the effectiveness of this programme remains
controversial.3–5 Furthermore, its performance cannot be
assessed directly, as there is no confirmatory diagnostic test. In
clinical practice, screen positive infants who are truly affected
cannot be distinguished from those who are not.6 Thus clinical
screening is associated with potential over-treatment of those
with false positive screening results,7 as well as with failures of
screening, diagnosis, and treatment in those who are
affected.8
In view of these uncertainties, there has been increasing
interest in alternative ultrasound based screening strategies.5
Static ultrasound images are used to assess the morphology of
the largely cartilaginous newborn hip joint, specifically the
depth of the acetabulum and the location of the femoral head
at rest, while dynamic images, obtained during a modified
Barlow test, are used to assess hip stability. Although the role
of ultrasound imaging is not defined in the current UK policy,
in practice both methods have crept into use in the UK, but
largely to assess infants with defined risk factors.9 In contrast,
in some European countries all infants receive a static
ultrasound examination. This has led to a subsequent
reduction in the incidence of surgery, but a marked increase in
the incidence of abduction splinting to levels some 40–70
times higher than the prevalence of DDH before screening was
introduced.10 11 The long term outcome for those who are
treated despite not being truly affected is an important
consideration since there are significant iatrogenic risks asso-
ciated with abduction splinting, notably avascular necrosis of
the femoral head.12 This may affect normal as well as initially
abnormal hips and, in its severest form, results in premature
osteoarthritis of the hip.13 14
In recognition of these concerns, the Department of Health
initiated research under the auspices of a MRC Working Party
to assess the current programme and the potential role of
ultrasound.6 This comprised observational epidemiological
studies,3 9 a randomised trial of ultrasound in the manage-
ment of neonatal clinical hip instability,15 16 and, as the most
appropriate approach to evaluating primary screening was
See end of article for
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unclear, an examination of existing evidence, which we report
here. The objective of this study is to identify those factors that
most influence the relative performance and effects of the dif-
ferent primary screening strategies in order to inform future
policy and research priorities. We report the performance,
treatment pathways, and effects of clinical and ultrasound
based screening strategies and “no screening”, using decision
tree models to synthesise data sources relevant to the United
Kingdom. The costs and efficiency of these different strategies
are reported in an accompanying paper.
METHODS
Definition of target condition
The term DDH refers to a spectrum of developmental
disorders of the hip,17 and includes dislocated or subluxated
hips where the femoral head is completely or partially
displaced from the acetabulum, or stable dysplastic hips where
the femoral head is stable and not displaced but the acetabu-
lum is dysplastic or shallow. It is unclear whether stable dys-
plastic hips,whichmay present symptomatically in early adult
life, share the same antecedents as dislocated or subluxated
hips, are preceded by dysplasia or instability in infancy, or are
modifiable by early treatment.4 We evaluated strategies to pre-
vent hip dislocation or subluxation, which usually presents
clinically and requires surgical treatment during early
childhood.6 18
Characterisation of strategies to be compared
Three screening strategies were identified (table 1). In a
“clinical screening alone” strategy, all infants are screened
with the Ortolani and Barlow tests whereby the examiner
attempts to reduce a dislocated hip and provoke dislocation or
subluxation respectively. Infants in whom one or both hips are
dislocated, subluxated, or unstable are referred for further
clinical, but not sonographic, assessment. In a universal ultra-
sound strategy, all infants receive a static and dynamic ultra-
sound examination in addition to clinical screening; those
with sonographic appearances of dislocation or instability
and/or a positive Ortolani or Barlow test are referred for
further clinical and sonographic assessment.19 In a selective
ultrasound strategy, all infants are screened clinically and
assessed for the presence of recognised risk factors: those with
a positive Ortolani and/or Barlow test and/or recognised risk
factors are referred for sonographic assessment.20 Thus, in this
strategy ultrasound is not used as a primary screening test. As
screening was introduced without clear evidence of benefit,
we included a “no screening” strategy, whereby infants are
diagnosed only following presentation with clinical signs or
symptoms.
In each screening strategy, infants who on referral have
persistent clinical or sonographic dislocation, subluxation, or
instability are treated with abduction splinting. Infants
treated with abduction splinting include those who would
develop DDH (true positives, treated early), as well as those
who would not (false positives, treated). Infants with a
positive screening result but in whom persistent abnormalities
are not confirmed at follow up include those who may present
clinically at a later stage, when abduction splinting is no
longer possible and surgery is required. They are also true
positives, but do not benefit from early treatment because of a
failure of diagnosis (true positives, treated late).8 Infants with
a negative screening result may present later with clinical
signs or symptoms (false negatives) or may remain clinically
well (true negatives). In the “no screening” option, infants can
only present symptomatically, and surgery, but not abduction
splinting, is the treatment option.
Development of a decision model
A decision tree was developed to depict the sequence of events
experienced by 100 000 liveborn infants along the screening,
management, and treatment pathways for each of the screen-
ing strategies (fig 1). A “no screening” strategy was included
to allow calculation of the incremental effects of screening.
Probabilities in the model assumed to vary by screening strat-
egy include: being screened (A), a positive screening result
(B), treatment with abduction splinting following a positive
screening result (C), treatment following a negative screening
result (E), and treatment following a positive screening result
that is not confirmed (F).We assumed that surgical treatment
would not be required in those infants with false positive
screening results. Otherwise the probability of surgical
treatment following abduction splinting (G) was assumed
constant for all screening strategies. The probability of DDH
among those infants who are not screened (D) was assumed
to be equivalent to the prevalence of DDH (see below). These
probabilities, as indicated by these letters, are shown in fig 1.
Favourable treatment outcomes
We defined a favourable treatment outcome as the radiological
absence of hip dislocation or subluxation at skeletal maturity.
Hip pain and range of movement during childhood are a poor
guide to normal hip development and function in adult life,21
while radiological appearances by skeletal maturity are
thought to predict symptomatic osteoarthritis and need for
hip replacement in early adult life. The probability of a favour-
able treatment outcome was assessed from reports of
radiological appearances of the hips at 16–24 years of age,
using the system devised by Severin.22 Severin hip scores of
4–6 imply hip dislocation or subluxation associated with
increasing degrees of joint deformity, while a score of 3
describes dysplastic (shallow) hips without evidence of
displacement. In the base case analysis, we defined a
favourable outcome as Severin hip scores of 1–3 in both hips
by 16 years. The probabilities of a favourable outcome differ
according to the treatment given and were only assigned fol-
lowing surgical or abduction splinting treatment of affected
children—that is, excluding abduction splinting treatment in
those with false positive screening results. We assumed that
Table 1 Definition of screening strategies
Screening strategy Screening test Positive test result
Clinical screening alone Ortolani and Barlow tests Clinically dislocated or subluxatable hip(s)
Universal ultrasound Ortolani and Barlow tests Clinically dislocated or subluxatable hip(s)
AND OR
Static and dynamic ultrasound imaging Sonographically displaced or unstable hip(s)
Selective ultrasound Ortolani and Barlow tests Clinically dislocated or subluxatable hip(s)
AND OR
Systematic identification of recognised risk factors for DDH* Presence of one or more risk factors
*DDH, developmental dysplasia of the hip. Recognised risk factors include breech (non-cephalic) presentation in third trimester or at delivery, and first
degree family history of DDH.
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they were similar in all strategies. The effect of omitting hip
dysplasia without displacement (Severin hip score 3) from the
favourable outcomes was explored in a sensitivity analysis.
Unfavourable treatment outcome
We selected avascular necrosis following surgical treatment or
abduction splinting as the principal unfavourable treatment
outcome. This was derived from published reports of
radiological appearances consistent with systems devised by
Kalamchi and MacEwen23 or Salter and colleagues,24 and
occurring in one or both hips when assessed at least two years
following surgical treatment or abduction splinting.
Estimation of probabilities to populate the decision
model
Probabilities were obtained from published and unpublished
data sources relevant to the United Kingdom, identified
through a computerised search of Medline (1966 to August
2001) and Embase (1974 to August 2001) using search
strategies modified from those developed for systematic
reviews,25 by scanning the reference lists of recent published
systematic reviews,26–29 and by contacting experts for unpub-
lished data. With the exception of four randomised
trials,20 30–32 the studies reviewed were observational studies.
Probability data were summarised adjusting as appropriate to
express data using children rather than hips as the
denominator (see tables A and B, available on the ADC
website; www.archdischild.com/supplemental). Sensitivity
analyses were performed using extreme but plausible values
as listed in web tables A and B, based when possible on ranges
reported in the literature. Details of the sensitivity analyses are
presented below and in an accompanying paper33 for those
parameters that were most influential or where there were
uncertainties that could potentially be addressed by changes
in policy.
The probability of abduction splinting in a universal
ultrasound strategy was based on data published from the
single UK centre operating such a policy19 34 to take account of
management practices and treatment thresholds likely to
operate in the UK. Estimates of abduction splinting rates
derived from other European programmes or from studies
incorporating universal ultrasound imaging were examined in
a sensitivity analysis.
Estimation of screening programme performance
In clinical practice, children with true positive and false posi-
tive screening results cannot be distinguished; screening pro-
gramme performance cannot therefore be calculated directly.
We enumerated the true positive screening results from the
decision model by adapting a method devised to estimate the
sensitivity and specificity of a screening test where a diagnos-
tic test is lacking.28 35 We assumed that all those with DDH
were treated with either surgery or abduction splinting, that
all those requiring surgical treatment have DDH, and that the
underlying prevalence of DDH has not changed since screen-
ing was introduced and is equivalent to the mid-point preva-
lence estimate for Northern European populations of 120 per
100 000 live births, derived from studies reported before
screening was introduced.36 We derived estimates of the rates
of surgical treatment with or without prior abduction
splinting associated with each screening strategy from the lit-
erature. Together with the prevalence estimate above, this
allowed calculation of the number treated with abduction
splinting who were true and false positives.
Modelling options for implementation
The expertise of the primary screener has been identified as an
important factor in the effectiveness of the current
policy.4 37–40 In the base case, we derived the false negative rate
(E in fig 1) for clinical screening alone from reports from UK
centres where junior medical staff are responsible for carrying
out the Ortolani and Barlow tests (web table A). We
investigated the potential impact of using more experienced
examiners by deriving a false negative rate from reports where
more experienced or specifically trained staff (physiothera-
pists or orthopaedic specialists) were responsible for clinical
screening (web table A). We also investigated the potential
impact of using ultrasound to inform the subsequent
management of infants with positive Ortolani or Barlow tests,
as assessed in the UKHip Trial,15 by assuming that this avoided
failures of diagnosis among those screening positive.8 Finally
Figure 1 Decision tree depicting
screening, treatment, and
management pathways for each of
the strategies. *Pathways for these
strategies are similar to those
depicted for clinical screening.
Clinical effects of alternative DDH screening policies 755
www.archdischild.com
 on 28 August 2008 adc.bmj.comDownloaded from 
we investigated a combination of these two modifications to
current policy.
Modelling uncertainties relevant to unfavourable
outcomes of screening
Uncertainties in specifying the risk factors to be used as indi-
cations for ultrasound examination in a selective ultrasound
strategy9 were investigated by varying the proportion of
children with a positive screening result (B in fig 1). Similarly,
uncertainties in ultrasound indications for abduction
splinting were investigated by varying the proportion of chil-
dren treated with abduction splinting in the ultrasound based
strategies (C in fig 1).
RESULTS
The performance of each of the different screening
strategies,41 estimated from the decisionmodel, is summarised
for 100 000 births in table 2. The percentage of infants with
positive screening results is highest for strategies based on
ultrasound, being 7.7% and 8.1% for universal and selective
use of ultrasound respectively, compared with 2.1% for clinical
screening alone. Ultrasound strategies are also associated with
a higher estimated detection rate: 76% and 60% for universal
and selective use of ultrasound respectively, compared with
35% for clinical screening alone. More false positive screening
results occur in strategies using ultrasound (table 2). Thus the
odds of being affected given a positive result are most favour-
able in the clinical examination strategy as a consequence of a
higher specificity.
Without screening, all affected children require surgical
treatment. This percentage is greatly reduced with screening
strategies using ultrasound (table 3). This occurs to a much
lesser extent in clinical screening alone, as in this screening
strategy there are more children with false negative screening
results or with true positive screening results that are
unconfirmed.8 By contrast, ultrasound based strategies are
associated with higher abduction splinting rates. In the base-
line model, the predicted number treated with abduction
splinting alone is higher for selective use of ultrasound rather
than universal ultrasound (table 3), reflecting the more
conservative estimate of treatment probabilities used in the
model for universal ultrasound.19 34 It is notable that, in all








Expected number with DDH* 120 120 120
Number not screened† 0 2000 0
Positive screening result, n (%) 2127 (2.1%) 7662 (7.7%) 8125 (8.1%)
True positives 42 92 71
False positives 2085 7570 8054
Negative screening result, n 97873 90338 91875
False negatives 78 26 49
True negatives 97795 90312 91826
Detection rate, % 35% 76% 60%
False positive rate, % 2.1% 7.6% 8.1%
Odds of being affected given a positive screening result 1:51 1:84 1:114
Numbers per 100000 live births, rounded to nearest whole number, unless otherwise stated.
*DDH, developmental dysplasia of the hip.
†Baseline assumption that all newborns are examined clinically and are assessed for recognised risk factors,
but that 2% miss ultrasound screening in a universal ultrasound programme as cited in Marks et al,19 giving
rise to two cases of DDH.
Table 3 Estimates of treatment given, favourable outcomes at skeletal maturity, and











Surgery alone 120 102 28 49
Abduction splinting alone 0 421 516 707
Abduction splinting and surgery 0 <1 2 2
Favourable treatment outcomes
Total 90 94 110 106
Not screened or not detected by screening 90 58 21 36
Detected by screening 0 36 89 70
Achieved without surgery 0 17 87 68
Avascular necrosis
Total 18 20 9 14
Not screened or not detected by screening 18 12 4 7
Detected by screening 0 8 5 7
Arising in infants with false positive diagnoses 0 4 4 6
Number per 100000 live births, rounded to nearest whole number.
*Within each strategy 120 infants per 100000 live born are expected to develop DDH.
756 Dezateux, Brown, Arthur, et al
www.archdischild.com
 on 28 August 2008 adc.bmj.comDownloaded from 
screening strategies, the majority of children treated with
abduction splinting alone have a false positive screening result
(403, 426, 638 respectively for clinical screening alone, univer-
sal, and selective use of ultrasound).
Our findings suggest that the effectiveness of clinical
screening, as performed in the UK, is only marginally better
than no screening. Without screening, 90 (75%) of the 120
cases of DDH anticipated among 100 000 live births would be
expected to have a favourable treatment outcome, compared
with 94 (78%) in a clinical screening alone strategy (table 3).
This compares with equivalent figures of 110 (92%) and 106
(88%) in universal and selective use of ultrasound respectively.
Furthermore, a higher percentage of these favourable out-
comes are achieved without recourse to surgery in ultrasound
based screening strategies: 79% with universal ultrasound,
64% with selective ultrasound, compared with 18% with clini-
cal screening alone.
Ultrasound based strategies are associated with the fewest
cases of avascular necrosis of the femoral head overall, reflect-
ing the fact that in these strategies fewer affected children
require surgery (table 3). Although the number of cases of
avascular necrosis which arise in unaffected children treated
with abduction splinting as a result of a false positive screen-
ing result is relatively similar across the screening strategies,
this represents a higher percentage of all avascular necrosis
cases in the ultrasound based strategies: 44% in selective
ultrasound, 43% in universal ultrasound, and 20% in clinical
screening alone.
Uncertainties in estimates of test performance, rates of
abduction splinting or surgery, or treatment effectiveness were
explored in sensitivity analyses. Omitting hip dysplasia with-
out displacement (Severin 3) from the favourable outcomes
(web table B) results in an absolute reduction of 20–25% in the
proportion of affected children with a favourable treatment
outcome in all strategies. Other relevant sensitivity analyses
are reported below.
Modelling options for implementation
The predicted detection rate of 35% for clinical screening alone
in the baseline model rises to 80%, comparable to that
reported for universal ultrasound,when the false negative rate
is derived from centres using more experienced or dedicated
screening examiners rather than junior medical staff. As a
consequence, the number of children requiring surgery falls
from 102 to 50 per 100 000, the percentage of affected children
with a favourable outcome rises from 78% to 88%, and the
percentage of these outcomes achieved without recourse to
surgery rises from 18% to 65%.
In the baseline analysis for clinical screening alone, failure
to confirm DDH in affected children who have screened posi-
tive (referred to as failures of diagnosis8) may result in nearly
60% of infants correctly identified through screening receiving
late (that is, surgical) treatment. If such cases were avoided by
using ultrasound to manage infants with a positive clinical
screening result,15 20 then the absolute number of favourable
treatment outcomes rises slightly from 94 to 99, but the
proportion of these achieved without recourse to surgery more
than doubles, rising from 18% to 37%. If both these modifica-
tions are considered together, then clinical screening alone
becomes the most effective option, with 111 favourable treat-
ment outcomes, and 84% achieved without surgery.
Uncertainties relevant to unfavourable outcomes of
screening
Uncertainty in specifying the risk factors to be used as indica-
tions for ultrasound examination in selective use of ultra-
sound was investigated by increasing the proportion of infants
with a positive screening result from the value of 8% used in
the base case to 13% as reported from some UK centres oper-
ating such a policy.42 In this scenario, were the probability of
abduction splinting to be unchanged, the number of infants
with false positive diagnoses who are treated unnecessarily
would rise from 638 to 1058.
Uncertainties regarding the ultrasound indications for
abduction splinting were investigated by increasing the
abduction splinting rate from 518 per 100 000 as reported
from the only UK based universal ultrasound programme19 to
reflect the experience of non-UK centres10 11 31 where, on aver-
age, 4400 per 100 000 are splinted (web table A). Given this
scenario, the number of children treated unnecessarily as a
consequence of a false positive screening result rises by a fac-
tor of 10, from 427 to 4309 per 100 000. Similarly, in selective
use of ultrasound, increasing the abduction splinting rate
from the baseline of 709 to 1417 per 100 000 as reported from
some UK centres, results in a doubling of those with a false
positive screening result from 637 to 1346 per 100 000.
DISCUSSION
The dilemmas arising from the lack of robust evidence to
inform screening policies for DDH are well rehearsed.5 29 While
screening policies should ideally be based on evidence from
randomised trials, in practice this option is often constrained
by considerations of cost, duration, and uncertainties in speci-
fying which options and outcomes to compare. Royston has
highlighted the complementarity of decisionmodels and trials
in appraising screening programmes.43 Our objective in using a
decision model to compare policy options based on data
relevant to a UK setting was to assess the extent to which
existing data can inform these policy decisions without
recourse to further primary research and to identify areas in
which future empirical research might be most useful for
policy.
Although there have been other published evaluations of
clinical and ultrasound based screening for DDH,26 29 34 44–46 our
approach has two important strengths which have not been
addressed previously. Firstly, we have enumerated true and
false positive screening results, allowing the performance and
potential harms of the different screening strategies to be
compared (otherwise only possible in trials comparing
screening with no screening). Secondly, we have compared
strategies in relation to longer term health outcomes relevant
to the goals of screening. This has allowed quantification of
the benefits and harms of each screening strategy at a popula-
tion level and identification of factors with most influence on
performance and effects.
One limitation relates to the quality of the literature from
which we derived probability estimates.26 29 These were based
almost entirely on observational data. Of four randomised or
quasi-randomised controlled trials,10 20 30 32 only two provided
information of potential relevance to this study.10 20 The lack of
randomised evaluations of the effectiveness of abduction
splinting is of particular concern, as infants with false positive
screening results cannot be identified clinically. We found
relatively few observational studies reporting long term
outcomes of abduction splinting or surgery relevant to a UK
setting, despite more than 30 years experience of clinical
screening in the UK.1 29 While recognising that surgical treat-
ment or false negative rates are not reported consistently in
the existing literature,29 47 and that outcome data are from
selected case series, this model has allowed the available evi-
dence to be examined and subjected to sensitivity analyses.
Of the screening strategies considered, universal ultrasound
appears to be associated with the highest number of
favourable outcomes as well as the highest proportion of these
achieved without requiring surgery. However, it is also associ-
ated with the highest risk of potential iatrogenic adverse
effects among those with a false positive screening result. The
performance of clinical screening alone is poor and only mar-
ginally better than no screening when based on themean false
negative rate derived from UK centres where junior medical
Clinical effects of alternative DDH screening policies 757
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staff undertake screening.9 This is no longer the case when
that estimate is based on the performance of more experi-
enced examiners (physiotherapists or orthopaedic surgeons).
Furthermore, these findings concur with previous observa-
tions that experience of the screening examiners accounts for
differences in the performance of programmes based on clini-
cal screening alone.3 4 26 29 40 48 This finding highlights the
importance of strategies to improve training in clinical
screening, training which is recognised to be patchy and
inconsistent in content in the UK.4 9 A recent prospective study
has shown that advanced neonatal nurse practitioners given a
structured training in clinical examination are more success-
ful in identifying persistent neonatal hip abnormalities than
junior doctors not given such a training.49
There is an almost threefold variation in the percentage of
infants referred for ultrasound between UK centres operating
selective ultrasound programmes. This reflects uncertainty in
the choice of “risk” factors9 29 and highlights the problems of
using risk factors with low predictive value as screening
tests50 as well as the difficulties in operationalising this
screening strategy. Breech presentation at delivery or in the
third trimester, female sex, and a family history of DDH are all
strongly associated with an increased risk of DDH in the
infant.26 51 However, in UK practice, postural foot deformities,
oligohydramnios, and clicking hips, which are less strongly
associated with DDH, are often included in the definition of
risk.9 41 52 In our decision model, we derived estimates of the
percentage identified with risk factors and the associated false
negative rates from published reports of such programmes,
but were not able, from the data available, to estimate the pre-
dictive value of individual risk factors in the absence of clini-
cal hip instability. However, the UK Hip Trial findings have
shown that the performance of clinical screening can be aug-
mented by using ultrasound to inform the management of
infants with clinically unstable hips through a reduction in
the risk of unnecessary treatment.15 The role of ultrasound and
the value of treatment in those infants without unstable hips
but with other risk factors is less clear.32 53
The effects of both ultrasound based strategies are also
influenced by rates of treatment with abduction splinting, and
this is most marked when these are derived from rates
reported from universal ultrasound programmes in other
European countries. At these levels, there are important nega-
tive consequences for the population screened, as the
subsequent increase in unnecessary treatment of infants with
false positive diagnoses is likely to result in an increase in
those with avascular necrosis. We have not enumerated other
risks reported to be associated with abduction splinting, but
these are not trivial and include femoral nerve palsies and
pressure sores, as well as parental anxiety.16
In conclusion, the decisionmodel presented enumerates the
benefits and harms of different screening strategies for DDH,
a necessary process in the explicit appraisal of policy options.
While ultrasound based strategies may appear to be more
effective than clinical screening or no screening, significant
uncertainties remain. These include uncertainties in the indi-
cations for ultrasound in a selective ultrasound strategy, as
well as in the ultrasound indications for treatment with
abduction splinting. Our findings also suggest that clinical
screening, as currently performed in the UK, is of marginal
benefit relative to no screening but could be improved by use
of more expert primary screening examiners who have been
specifically trained to screen and by using ultrasound to assess
infants with positive screening results. This is consistent with
the experience of those implementing a recent quality
improvement initiative in Northern Ireland which focused on
staff training and careful assessment of high risk infants.54
Further research is required to assess the effectiveness of
abduction splinting, particularly in those with stable hips but
with ultrasound appearances of dysplasia and/or recognised
risk factors.32 While structured training for advanced neonatal
nurse practitioners appears promising,49 further work is
needed to develop training and methods of assessing
performance in clinical screening. Equally there is a need to
define methods, standards, training, and accreditation in
ultrasound imaging of the infant hip, particularly for dynamic
imaging. Finally, prospective assessment of the longer term
outcomes of surgical and abduction splinting treatment is
required.
In policy terms, decisions to stop or modify established
screening programmes introduced without prior evaluation
require evidence which is often by definition lacking. This
model has explored a range of policy and implementation
options in a UK setting which decision makers might like to
consider. However, the costs and efficiency of these options
need further evaluation to provide a basis for informed policy
discussion. These are assessed in the accompanying paper.33
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